[go: up one dir, main page]

GR1010821B - Stable homogenized pharmaceutical nasal suspension of azelastin-and-fluticazone combination - Google Patents

Stable homogenized pharmaceutical nasal suspension of azelastin-and-fluticazone combination Download PDF

Info

Publication number
GR1010821B
GR1010821B GR20230100932A GR20230100932A GR1010821B GR 1010821 B GR1010821 B GR 1010821B GR 20230100932 A GR20230100932 A GR 20230100932A GR 20230100932 A GR20230100932 A GR 20230100932A GR 1010821 B GR1010821 B GR 1010821B
Authority
GR
Greece
Prior art keywords
fluticazone
azelastin
pharmaceutical nasal
combination
nasal suspension
Prior art date
Application number
GR20230100932A
Other languages
Greek (el)
Inventor
Εργινα Ηλια Πενταφραγκα
Βαρβαρα Ζουμπλιου
Original Assignee
Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, filed Critical Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια,
Priority to GR20230100932A priority Critical patent/GR1010821B/en
Publication of GR1010821B publication Critical patent/GR1010821B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a stable homogenized pharmaceutical nasal suspension combining azelastine and fluticasone. In particular, said suspension containing azelastine hydrochloride, fluticasone propionate and polysorbate 80 is substantially free of fluticasone degradation products. The preparation method of the above stable homogenized pharmaceutical nasal suspension and the use thereof are part of this invention.
GR20230100932A 2023-11-09 2023-11-09 Stable homogenized pharmaceutical nasal suspension of azelastin-and-fluticazone combination GR1010821B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GR20230100932A GR1010821B (en) 2023-11-09 2023-11-09 Stable homogenized pharmaceutical nasal suspension of azelastin-and-fluticazone combination

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20230100932A GR1010821B (en) 2023-11-09 2023-11-09 Stable homogenized pharmaceutical nasal suspension of azelastin-and-fluticazone combination

Publications (1)

Publication Number Publication Date
GR1010821B true GR1010821B (en) 2024-11-15

Family

ID=93926796

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20230100932A GR1010821B (en) 2023-11-09 2023-11-09 Stable homogenized pharmaceutical nasal suspension of azelastin-and-fluticazone combination

Country Status (1)

Country Link
GR (1) GR1010821B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105856A1 (en) * 2002-06-14 2003-12-24 Cipla Limited Combination of azelastine and steroids
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
WO2014092346A1 (en) * 2012-12-12 2014-06-19 Hanmi Pharm. Co., Ltd. Bitter taste masked pharmaceutical formulation comprising corticosteroid, antihistamine and stevia
CN107320449A (en) * 2017-08-07 2017-11-07 武汉武药科技有限公司 Fluticasone propionate nasal spray and preparation method thereof
US20230218630A1 (en) * 2020-06-15 2023-07-13 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
WO2024063712A1 (en) * 2022-09-20 2024-03-28 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105856A1 (en) * 2002-06-14 2003-12-24 Cipla Limited Combination of azelastine and steroids
WO2011141929A2 (en) * 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
WO2014092346A1 (en) * 2012-12-12 2014-06-19 Hanmi Pharm. Co., Ltd. Bitter taste masked pharmaceutical formulation comprising corticosteroid, antihistamine and stevia
CN107320449A (en) * 2017-08-07 2017-11-07 武汉武药科技有限公司 Fluticasone propionate nasal spray and preparation method thereof
US20230218630A1 (en) * 2020-06-15 2023-07-13 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
WO2024063712A1 (en) * 2022-09-20 2024-03-28 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising azelastine hci, fluticasone propionate and relevant excipients

Similar Documents

Publication Publication Date Title
PL373001A1 (en) Combination of azelastine and steroids
TW329387B (en) Pharmaceutical composition for treating airway passage and lung diseases comprising mometasone furoate
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
MY196599A (en) Pharmaceutical compositons comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
DE69636531D1 (en) METHOD, COMPOSITIONS AND KITS FOR INCREASING THE ORAL BIOVERABILITY OF PHARMACEUTICALS
HUP0104718A2 (en) Micronized eplerenone compositions and process for their preparation
PH12022552172A1 (en) High concentration anti-a㟠protofibril antibody formulations and methods of use thereof
CR20230143A (en) Piperidinyl small molecule degraders of helios and methods of use
NO20071044L (en) Dosage forms with enterally coated tablet cores
PH12021551232A1 (en) Haloallylamine compounds and application thereof
BRPI0409434A (en) nasal pharmaceutical formulations and methods for using them
MX2023009971A (en) Pharmaceutical composition containing anti-tslp antibody.
GR1010821B (en) Stable homogenized pharmaceutical nasal suspension of azelastin-and-fluticazone combination
EA200500328A1 (en) COMPOSITION AND MEDICINE FOR THE TREATMENT OF RESPIRATORY DISEASES, ALLERGIC DISEASES, ASTHMA AND / OR CHRONIC OBSTRUCTIVE PULMONARY DISEASES AND METHOD FOR OBTAINING MEDICAL TREATMENTS
UA42719C2 (en) Compositions and methods for the treatment of immunomediated inflammatory disorders
AU2008253776A8 (en) Agent, pharmaceutical composition, and method for treating the ethyl alcohol and/or narcotic dependence
MX2022012967A (en) Treatment of hidradenitis suppurativa.
MX2021012782A (en) The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations.
RU2220740C1 (en) Agent for treatment of allergic rhinitis and allergic conjunctivitis
HUP0202753A2 (en) Pharmaceutical compositions containing novel combination of loteprednol and b2-adrenoceptor agonists and their use
MX2022011651A (en) Method for treating diabetes.
MX2023003878A (en) Succinate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1 -yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same.
MX2022008655A (en) Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components.
EA202000218A1 (en) PHARMACEUTICAL COMPOSITION (OPTIONS), APPLICATION OF PHARMACEUTICAL COMPOSITION (OPTIONS)
ZA202207992B (en) Pharmaceutical composition of extended-release oral suspension and process for preparation thereof

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20241209